Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChristian BuskeAGAlexander GrunenbergLMLydia Montes

Discussion

Loading...

Member takes

Overview

Randomised trial shows superior efficacy of Dexamethasone and Rituximab with Bortezomib in Waldenström's Macroglobulinemia, indicating potential as standard therapy.

Key Points

  • This analysis evaluates the treatment efficacy and safety of Dexamethasone, Rituximab, Cyclophosphamide, and Bortezomib in patients with Waldenström's Macroglobulinemia.
  • Prospective randomized multicenter trial (ECWM-1) with 204 registered patients
  • Patients received 6 cycles of Dexamethasone, Rituximab and Cyclophosphamide (DRC) or DRC with Bortezomib (B-DRC)
  • Follow-up duration averaged 68.8 months with evaluation of progression-free survival (PFS) and safety profile
  • Median PFS for B-DRC was 56.7 months compared to 50.1 months for DRC (p=0.64)
  • Overall survival (OS) at 5 years was 90% across both treatment arms
  • Addition of Bortezomib resulted in a numerically higher response rate but was not statistically significant

Cite This Study

Buske et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc5fhttps://doi.org/10.1182/blood-2025-223
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre2026 · 1 citations
  2. 2Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network2024
  3. 3A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 )2025
  4. 4Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia2025 · 1 citations
  5. 5PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia2024 · 4 citations